Tykerb, Tyverb (lapatinib) is a small molecule pharmaceutical. Lapatinib was first approved as Tykerb on 2007-03-13. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against epidermal growth factor receptor and receptor tyrosine-protein kinase erbB-2. Tykerb's patent is valid until 2029-09-18 (FDA).
|Drug Class||Tyrosine kinase inhibitors|